Cromos Pharma attends Asia Matters briefing

21 January 2020

Cromos Pharma Ireland was delighted to be invited to attend a very special event highlighting trade links between Ireland and Japan (January 17, 2020) in Dublin. The Asia Matters event was hosted by PwC Ireland. The keynote speaker at the event was Ireland’s Ambassador to Japan Paul Kavanagh (@IrishEmbJapanEN). He discussed the growing trade relations between the two countries and the Irish government’s commitment to strengthening these links through its Global Ireland: Asia-Pacific Strategy.

Cromos Pharma’s Managing Director Andrey Tarakanov says, “We are delighted to take part in this Asia Matters Japan Business Briefing. It is an honor to meet with Ambassador Paul Kavanagh and hear about Ireland’s Global Ireland Asia-Pacific Strategy. Cromos Pharma Ireland is currently engaged in exploring trade relations with Japan in the area of clinical research and greatly welcomes the opportunity to learn more about links between the two countries. The Irish government’s strategy to double its impact in Asia-Pacific is an exciting new direction and we look forward to discovering more about doing business in Japan.”

Pictured at the event

Pictured at the event (l-r): Ambassador Paul Kavanagh; Mary Honohan, PwC Ireland; Noel Quinn and Andrey Tarakanov, Cromos Pharma Ireland.

Global Ireland is a multi-annual, whole-of-government strategy to double the scope and impact of Ireland’s global footprint by 2025. It is the most ambitious renewal and expansion of Ireland’s international presence ever undertaken. A new Asia-Pacific strategy was launched in later 2019 and is part of its Asian strategy it aims to double Ireland’s impact in the Asia Pacific region by 2025.

Cromos Pharma is an international clinical research organization with its European HQ in Dublin, Ireland. It operates clinical research services in 15 countries worldwide with specific expertise in Eastern and Central Europe. As part of its global business strategy Cromos Pharma is growing its presence in the EU, US and Asia-Pacific markets.


Back to the news